EUCTR2019-000587-23-DE进行中（未招募）1 期
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) - DOR/ISL Blinded Label Switch
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 578
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Is HIV-1 positive with plasma HIV-1 RNA <50 copies/mL at screening
- •2.Has been receiving BIC/FTC/TAF therapy with documented viral suppression (HIV-1 RNA <50 copies/mL) for =3 months prior to signing informed consent and has no history of prior virologic treatment failure on any past or current regimen
- •3.Is male or female, at least 18 years of age at the time of signing the informed consent
- •4.A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •-Is not a woman of childbearing potential (WOCBP) or
- •-Is a WOCBP and using an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 6 weeks, corresponding to the time needed to eliminate any study intervention(s) (eg, 5 terminal half-lives) after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention
- •-A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention
- •-If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive
- •-The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy
- •5.The participant (or legally acceptable representative) has provided documented informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 550
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •1.Has HIV-2 infection
- •2.Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator
- •3.Has an active diagnosis of hepatitis due to any cause, including active HBV coinfection (defined as HBsAg-positive or HBV DNA positive)
- •4.Has a history of malignancy =5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi’s sarcoma
- •5.Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate
- •6.Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies from 45 days prior to Day 1 through the study treatment period
- •7.Is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to Day 1 through the study treatment period
- •8.Has a documented or known virologic resistance to DOR, as demonstrated by any of the following DOR resistance substitutions in reverse transcriptase: V106A/M, V108I, Y188L, H221Y, P225H, F227C/L, M230I/L, L234I, P236L, or Y318F
- •9.Has exclusionary laboratory values (completed by the central laboratory) within 45 days prior to Day 1
- •10.Is female and expecting to conceive or donate eggs at any time during the study
研究者
相似试验
进行中（未招募）
1 期
Oral ISL QM as PrEP in MSM and TGW at High Risk for HIV-1 InfectioHIV Preexposure prophylaxisMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2020-003309-79-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
进行中（未招募）
不适用
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese InfantsEUCTR2014-004181-21-Outside-EU/EEAPfizer Japan, Inc.551
已完成
3 期
Oral ISL QM as PrEP in MSM and TGW at High Risk for HIV-1 InfectioJPRN-jRCT2031200419Tanaka Yoshiyuki1,500
进行中（未招募）
1 期
Clinical Study to evaluate a switch to Doravirine/Islatravir in Participants with HIV-1 Virologically Suppressed on treatment with Bictegravir/Emtricitabine/Tenofovir AlafenamideHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2019-000587-23-FIMerck Sharp & Dohme LLC578
暂停
3 期
DOR/ISL 100 mg/0.25 mg QD in HIV-1 antiretroviral treatment naiveHIV-1 InfectionJPRN-jRCT2031220720Tanaka Yoshiyuki500